Additionally, ICAM1 and CD44 may have compensatory effects to maintain the dry characteristics of esophageal squamous cell carcinoma, indicating multiple targeted therapies that can be combined and considered in cancer treatment (Tsai et al., 2015). This evidence concerns the gene CD44 and esophageal squamous cell carcinoma.